Dermatology and Immune Response - Clinical Research Informer

Health Canada to review Arcutis’ roflumilast cream NDS for plaque psoriasis

Pharmaceutical Technology

JULY 12, 2022

A validated target in dermatology, PDE4 is an enzyme that induces overactive immune responses. Arcutis is establishing operations in Canada, and we have begun to build out a strong team with deep dermatology and commercialisation experience to support the future approval and launch.”.

Dermatology

Dermatology Immune Response Trials Clinical Trials

Study reveals details of immune defense guidance system

Scienmag

MARCH 3, 2021

Results could lead to better drugs used to fight inflammation At the beginning of an immune response, a molecule known to mobilize immune cells into the bloodstream, where they home in on infection sites, rapidly shifts position, a new study shows.

Immune Response

Immune Response Drugs Research Dermatology

Lilly’s lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials

The Pharma Data

AUGUST 16, 2021

AD, also known as atopic eczema, is a chronic inflammatory skin disorder caused by skin barrier dysfunction and dysregulation of the immune response. associate professor of dermatology at George Washington University School of Medicine and Health Sciences in Washington, DC, and a principal investigator of the ADvocate 2 trial.

Dermatology

Dermatology Trials Bioavailability Medicine

What is Hidradenitis Suppurativa: Signs, Causes and Treatments

Olympian Clinical Research

NOVEMBER 16, 2022

According to the American Academy of Dermatology , scientists believe that when a hair follicle becomes clogged with keratin, bacteria breed within it. HS is believed to develop due to an immune response that generates too much inflammation. Possible Causes of Hidradenitis Suppurativa. It’s also not caused by poor hygiene.

Clinical Research

Clinical Research Bacteria Dermatology Immune Response

Next Generation Complement Therapeutics: Potential Life-Changing Therapies for Multiple Rare Disorders

Roots Analysis

MARCH 3, 2022

The complement-targeted therapeutics inhibit complement activation, thereby reducing tissue inflammation and dampening the adaptive immune response to foreign and tissue antigens. Next Generation Complement Therapeutics – Current Market Landscape. Next Generation Complement Therapeutics. Broad Clinical Trial Landscape.

Drug Delivery Systems

Drug Delivery Systems Marketing Immune Response Dermatology

FDA clears Dupixent as first drug for rare skin disorder

pharmaphorum

SEPTEMBER 29, 2022

The disorder – driven by type 2 inflammation characterised by an antibody-based immune response – causes hard lumps or nodules to form on the skin that are so itchy they can lead patients to scratch themselves to the point of bleeding or pain.

Drugs

Drugs Immune Response Allergies Sales

Novel drug combo activates natural killer cell immunity to destroy cancer cells

The Pharma Data

JUNE 19, 2022

This occurs occurs over time as cancer patients are treated with drugs to enhance T-cell mediated immunity,” said Gavin Robertson, professor of pharmacology, pathology, dermatology and surgery, Penn State College of Medicine. They conducted their first experiment with cultured mouse melanoma cells.

Drugs

Drugs Protein Immune Response Dermatology

New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years

The Pharma Data

APRIL 28, 2021

These and other data from real-world settings and clinical trials, including the Dupixent open-label extension (OLE) trials, will be presented at the American Academy of Dermatology (AAD VMX 2021), April 23-25, and at the 20 th European Society for Pediatric Dermatology Annual Meeting (ESPD 2021), May 12-14.

Dermatology

Dermatology Trials Clinical Trials Clinical Trials

New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favorable

The Pharma Data

MARCH 16, 2021

These data will be presented virtually in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference, March 16–20, 2021. 9 The PsA approval was based on results from DISCOVER-1 and DISCOVER-2, which showed TREMFYA reached each study’s primary endpoint of ACR 20 response at 24 weeks.

Medicine

Medicine Doctors Doctor Development

Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis

The Pharma Data

OCTOBER 9, 2021

Ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), is characterized by an irregular, chronic immune response that creates inflammation and ulcers (sores) in the mucosa (lining) of the large intestine (colon) or rectum. Deucravacitinib is not approved for use in any country. About Ulcerative Colitis.

Trials

Trials Immune Response Dermatology Clinical Trials

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

The Pharma Data

SEPTEMBER 15, 2020

Based on the acceptable safety profile and the favorable immune response data, including the 4th dose response data, Pfizer received Breakthrough Therapy Designation. 20vPnC showed a safety and tolerability profile that was similar to Prevnar 13 ® Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein].

Gene Therapy

Gene Therapy Vaccination Vaccine Trials

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

The Pharma Data

APRIL 4, 2023

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue and can affect more than one body system simultaneously. Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.

FDA Approval

FDA Approval Containment Hormones Dermatology

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Monotherapy Post-Sorafenib Hepatocellular Carcinoma U.S. Indication

The Pharma Data

JULY 23, 2021

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Hormones

Hormones Trials Genome Genomics

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Hepatocellular Carcinoma U.S. Indication

The Pharma Data

MARCH 11, 2021

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials

Trials Hormones Genome Genomics

CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival

The Pharma Data

AUGUST 11, 2020

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials

Trials Hormones Clinical Trials Clinical Trials

CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers

The Pharma Data

AUGUST 11, 2020

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials

Trials Hormones Clinical Trials Clinical Trials

Clinical Research Informer

Health Canada to review Arcutis’ roflumilast cream NDS for plaque psoriasis

Study reveals details of immune defense guidance system

Trending Sources

Lilly’s lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials

What is Hidradenitis Suppurativa: Signs, Causes and Treatments

Next Generation Complement Therapeutics: Potential Life-Changing Therapies for Multiple Rare Disorders

FDA clears Dupixent as first drug for rare skin disorder

Novel drug combo activates natural killer cell immunity to destroy cancer cells

New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years

New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favorable

Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Monotherapy Post-Sorafenib Hepatocellular Carcinoma U.S. Indication

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Hepatocellular Carcinoma U.S. Indication

CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival

CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers

Stay Connected